(Q50903093)

English

Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up.

scientific article published on 26 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ingrid E Lundberg

10

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

Vivianne Malmström

9

object named as

Vivianne Malmström

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

6

object named as

Petra Amoudruz

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

Jennifer Pieper

5

object named as

Jennifer Pieper

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

Sevim Barbasso Helmers

7

object named as

Sevim Barbasso Helmers

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

author name string

Mei Zong

1

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

Christina Dorph

2

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

Maryam Dastmalchi

3

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

Helene Alexanderson

4

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

Inger Nennesmo

8

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

language of work or name

0 references

publication date

26 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

73

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

5

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

913-920

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

Polymyositis and dermatomyositis (first of two parts)

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Polymyositis and dermatomyositis (second of two parts)

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Polymyositis, dermatomyositis and inclusion-body myositis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Progress in inflammatory myopathies: good but not good enough

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Azathioprine with prednisone for polymyositis. A controlled, clinical trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

A clinical, serological, and histopathological study of myositis patients with and without anti-RNP antibodies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Tumor necrosis factor as a therapeutic target of rheumatologic disease

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Inclusion body myositis and myopathies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

International consensus on preliminary definitions of improvement in adult and juvenile myositis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor α expression in muscle tissue of patients with polymyositis or dermatomyositis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Successful treatment of acute visual loss in Muckle-Wells syndrome with interleukin 1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Do studies in humans better depict Th17 cells?

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Interleukin-1? expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: Important pathogenic features independent of inflammatory cell clusters in muscl

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202857

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2012-202857

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23625983

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50903093&oldid=2117135602"